Relations actives
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| John Gordon Foulkes | M | - |
Lipidio Pharmaceuticals, Inc.
 Lipidio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lipidio Pharmaceuticals, Inc. develops and manufactures medicines. It focuses on developing drugs to treat diseases associated with excess body fat and its lead program, GDD3898, is being investigated for the treatment of nonalcoholic steatohepatitis (NASH) and Prader Willi syndrome (PWS), an orphan disease, and anti-psychotic drug induced weight gain (AIWG). The company was founded by Jay Edward Birnbaum and is headquartered San Diego, CA.
Thirona Bio, Inc.
 Thirona Bio, Inc. Pharmaceuticals: MajorHealth Technology Thirona Bio, Inc. is an American biopharmaceutical company that focuses on developing drugs for fibrotic diseases. Thirona Bio is based in an undisclosed location. The private company's target indications include scleroderma, keloid scars, and certain cancers where there are no effective therapies. The company's unique approach uses a potent, topically applied drug to inhibit TGF-? "locally," minimizing the potential risk of systemic toxicity. The company was founded by John Gordon Foulkes, Jay Edward Birnbaum, K. George Mooney, and David A. Bullough, with John Gordon Foulkes serving as the CEO since incorporation. | - |
| Jay Birnbaum | M | 79 |
Thirona Bio, Inc.
Thirona Bio, Inc. Pharmaceuticals: MajorHealth Technology Thirona Bio, Inc. is an American biopharmaceutical company that focuses on developing drugs for fibrotic diseases. Thirona Bio is based in an undisclosed location. The private company's target indications include scleroderma, keloid scars, and certain cancers where there are no effective therapies. The company's unique approach uses a potent, topically applied drug to inhibit TGF-? "locally," minimizing the potential risk of systemic toxicity. The company was founded by John Gordon Foulkes, Jay Edward Birnbaum, K. George Mooney, and David A. Bullough, with John Gordon Foulkes serving as the CEO since incorporation.
Lipidio Pharmaceuticals, Inc.
Lipidio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lipidio Pharmaceuticals, Inc. develops and manufactures medicines. It focuses on developing drugs to treat diseases associated with excess body fat and its lead program, GDD3898, is being investigated for the treatment of nonalcoholic steatohepatitis (NASH) and Prader Willi syndrome (PWS), an orphan disease, and anti-psychotic drug induced weight gain (AIWG). The company was founded by Jay Edward Birnbaum and is headquartered San Diego, CA. | - |
| Nancy Hutson | M | 74 |
Lipidio Pharmaceuticals, Inc.
Lipidio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lipidio Pharmaceuticals, Inc. develops and manufactures medicines. It focuses on developing drugs to treat diseases associated with excess body fat and its lead program, GDD3898, is being investigated for the treatment of nonalcoholic steatohepatitis (NASH) and Prader Willi syndrome (PWS), an orphan disease, and anti-psychotic drug induced weight gain (AIWG). The company was founded by Jay Edward Birnbaum and is headquartered San Diego, CA.
Thirona Bio, Inc.
Thirona Bio, Inc. Pharmaceuticals: MajorHealth Technology Thirona Bio, Inc. is an American biopharmaceutical company that focuses on developing drugs for fibrotic diseases. Thirona Bio is based in an undisclosed location. The private company's target indications include scleroderma, keloid scars, and certain cancers where there are no effective therapies. The company's unique approach uses a potent, topically applied drug to inhibit TGF-? "locally," minimizing the potential risk of systemic toxicity. The company was founded by John Gordon Foulkes, Jay Edward Birnbaum, K. George Mooney, and David A. Bullough, with John Gordon Foulkes serving as the CEO since incorporation. | - |
| Daniel Petree | M | 68 |
Lipidio Pharmaceuticals, Inc.
Lipidio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lipidio Pharmaceuticals, Inc. develops and manufactures medicines. It focuses on developing drugs to treat diseases associated with excess body fat and its lead program, GDD3898, is being investigated for the treatment of nonalcoholic steatohepatitis (NASH) and Prader Willi syndrome (PWS), an orphan disease, and anti-psychotic drug induced weight gain (AIWG). The company was founded by Jay Edward Birnbaum and is headquartered San Diego, CA. | - |
| Charles Berkman | M | 55 |
Metabasis Therapeutics, Inc.
 Metabasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Metabasis Therapeutics, Inc. engages in discovery, development and commercialization of novel drugs for metabolic diseases using the proprietary technology and the knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases. Metabasis was incorporated in April 1997 and is headquartered in La Jolla, CA. | 14 ans |
| Lynda Kay Chandler | F | - |
Thirona Bio, Inc.
Thirona Bio, Inc. Pharmaceuticals: MajorHealth Technology Thirona Bio, Inc. is an American biopharmaceutical company that focuses on developing drugs for fibrotic diseases. Thirona Bio is based in an undisclosed location. The private company's target indications include scleroderma, keloid scars, and certain cancers where there are no effective therapies. The company's unique approach uses a potent, topically applied drug to inhibit TGF-? "locally," minimizing the potential risk of systemic toxicity. The company was founded by John Gordon Foulkes, Jay Edward Birnbaum, K. George Mooney, and David A. Bullough, with John Gordon Foulkes serving as the CEO since incorporation. | - |
| K. George Mooney | M | - |
Thirona Bio, Inc.
Thirona Bio, Inc. Pharmaceuticals: MajorHealth Technology Thirona Bio, Inc. is an American biopharmaceutical company that focuses on developing drugs for fibrotic diseases. Thirona Bio is based in an undisclosed location. The private company's target indications include scleroderma, keloid scars, and certain cancers where there are no effective therapies. The company's unique approach uses a potent, topically applied drug to inhibit TGF-? "locally," minimizing the potential risk of systemic toxicity. The company was founded by John Gordon Foulkes, Jay Edward Birnbaum, K. George Mooney, and David A. Bullough, with John Gordon Foulkes serving as the CEO since incorporation. | - |
| John Higgins | M | 54 |
Metabasis Therapeutics, Inc.
Metabasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Metabasis Therapeutics, Inc. engages in discovery, development and commercialization of novel drugs for metabolic diseases using the proprietary technology and the knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases. Metabasis was incorporated in April 1997 and is headquartered in La Jolla, CA. | 14 ans |
| John P. Sharp | M | 59 |
Metabasis Therapeutics, Inc.
Metabasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Metabasis Therapeutics, Inc. engages in discovery, development and commercialization of novel drugs for metabolic diseases using the proprietary technology and the knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases. Metabasis was incorporated in April 1997 and is headquartered in La Jolla, CA. | 14 ans |
| Molly A. Holman | M | - |
Metabasis Therapeutics, Inc.
Metabasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Metabasis Therapeutics, Inc. engages in discovery, development and commercialization of novel drugs for metabolic diseases using the proprietary technology and the knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases. Metabasis was incorporated in April 1997 and is headquartered in La Jolla, CA. | 16 ans |
| John P. Montana | M | - |
Thirona Bio, Inc.
Thirona Bio, Inc. Pharmaceuticals: MajorHealth Technology Thirona Bio, Inc. is an American biopharmaceutical company that focuses on developing drugs for fibrotic diseases. Thirona Bio is based in an undisclosed location. The private company's target indications include scleroderma, keloid scars, and certain cancers where there are no effective therapies. The company's unique approach uses a potent, topically applied drug to inhibit TGF-? "locally," minimizing the potential risk of systemic toxicity. The company was founded by John Gordon Foulkes, Jay Edward Birnbaum, K. George Mooney, and David A. Bullough, with John Gordon Foulkes serving as the CEO since incorporation. | - |
| Raksha Shah | M | - |
Lipidio Pharmaceuticals, Inc.
Lipidio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lipidio Pharmaceuticals, Inc. develops and manufactures medicines. It focuses on developing drugs to treat diseases associated with excess body fat and its lead program, GDD3898, is being investigated for the treatment of nonalcoholic steatohepatitis (NASH) and Prader Willi syndrome (PWS), an orphan disease, and anti-psychotic drug induced weight gain (AIWG). The company was founded by Jay Edward Birnbaum and is headquartered San Diego, CA. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Mark D. Erion | M | 66 |
Metabasis Therapeutics, Inc.
Metabasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Metabasis Therapeutics, Inc. engages in discovery, development and commercialization of novel drugs for metabolic diseases using the proprietary technology and the knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases. Metabasis was incorporated in April 1997 and is headquartered in La Jolla, CA. | 12 ans |
| Tran Nguyen | M | 50 |
Metabasis Therapeutics, Inc.
Metabasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Metabasis Therapeutics, Inc. engages in discovery, development and commercialization of novel drugs for metabolic diseases using the proprietary technology and the knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases. Metabasis was incorporated in April 1997 and is headquartered in La Jolla, CA. | 1 ans |
| Paul Laikind | M | 68 |
Metabasis Therapeutics, Inc.
Metabasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Metabasis Therapeutics, Inc. engages in discovery, development and commercialization of novel drugs for metabolic diseases using the proprietary technology and the knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases. Metabasis was incorporated in April 1997 and is headquartered in La Jolla, CA. | 13 ans |
| John W. Beck | M | 64 |
Metabasis Therapeutics, Inc.
Metabasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Metabasis Therapeutics, Inc. engages in discovery, development and commercialization of novel drugs for metabolic diseases using the proprietary technology and the knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases. Metabasis was incorporated in April 1997 and is headquartered in La Jolla, CA. | 10 ans |
| David Hale | M | 75 |
Metabasis Therapeutics, Inc.
Metabasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Metabasis Therapeutics, Inc. engages in discovery, development and commercialization of novel drugs for metabolic diseases using the proprietary technology and the knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases. Metabasis was incorporated in April 1997 and is headquartered in La Jolla, CA. | 13 ans |
| Barry Gumbiner | M | 68 |
Metabasis Therapeutics, Inc.
Metabasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Metabasis Therapeutics, Inc. engages in discovery, development and commercialization of novel drugs for metabolic diseases using the proprietary technology and the knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases. Metabasis was incorporated in April 1997 and is headquartered in La Jolla, CA. | 3 ans |
| Arnold Lewis Oronsky | M | 83 |
Metabasis Therapeutics, Inc.
Metabasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Metabasis Therapeutics, Inc. engages in discovery, development and commercialization of novel drugs for metabolic diseases using the proprietary technology and the knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases. Metabasis was incorporated in April 1997 and is headquartered in La Jolla, CA. | 10 ans |
| George F. Schreiner | M | 74 |
Metabasis Therapeutics, Inc.
Metabasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Metabasis Therapeutics, Inc. engages in discovery, development and commercialization of novel drugs for metabolic diseases using the proprietary technology and the knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases. Metabasis was incorporated in April 1997 and is headquartered in La Jolla, CA. | 3 ans |
| Daniel Burgess | M | 62 |
Metabasis Therapeutics, Inc.
Metabasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Metabasis Therapeutics, Inc. engages in discovery, development and commercialization of novel drugs for metabolic diseases using the proprietary technology and the knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases. Metabasis was incorporated in April 1997 and is headquartered in La Jolla, CA. | 6 ans |
| Heinz W. Gschwend | M | - |
Metabasis Therapeutics, Inc.
Metabasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Metabasis Therapeutics, Inc. engages in discovery, development and commercialization of novel drugs for metabolic diseases using the proprietary technology and the knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases. Metabasis was incorporated in April 1997 and is headquartered in La Jolla, CA. | - |
| William R. Rohn | M | 80 |
Metabasis Therapeutics, Inc.
Metabasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Metabasis Therapeutics, Inc. engages in discovery, development and commercialization of novel drugs for metabolic diseases using the proprietary technology and the knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases. Metabasis was incorporated in April 1997 and is headquartered in La Jolla, CA. | 6 ans |
| William Forbes | M | 62 |
Metabasis Therapeutics, Inc.
Metabasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Metabasis Therapeutics, Inc. engages in discovery, development and commercialization of novel drugs for metabolic diseases using the proprietary technology and the knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases. Metabasis was incorporated in April 1997 and is headquartered in La Jolla, CA. | 2 ans |
| Edgardo Baracchini | M | 64 |
Metabasis Therapeutics, Inc.
Metabasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Metabasis Therapeutics, Inc. engages in discovery, development and commercialization of novel drugs for metabolic diseases using the proprietary technology and the knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases. Metabasis was incorporated in April 1997 and is headquartered in La Jolla, CA. | 7 ans |
| Howard L. Foyt | M | 69 |
Metabasis Therapeutics, Inc.
Metabasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Metabasis Therapeutics, Inc. engages in discovery, development and commercialization of novel drugs for metabolic diseases using the proprietary technology and the knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases. Metabasis was incorporated in April 1997 and is headquartered in La Jolla, CA. | 2 ans |
| R. Wayne Frost | M | 69 |
Metabasis Therapeutics, Inc.
Metabasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Metabasis Therapeutics, Inc. engages in discovery, development and commercialization of novel drugs for metabolic diseases using the proprietary technology and the knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases. Metabasis was incorporated in April 1997 and is headquartered in La Jolla, CA. | - |
| Patricia Millican | F | 51 |
Metabasis Therapeutics, Inc.
Metabasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Metabasis Therapeutics, Inc. engages in discovery, development and commercialization of novel drugs for metabolic diseases using the proprietary technology and the knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases. Metabasis was incorporated in April 1997 and is headquartered in La Jolla, CA. | 3 ans |
| Elizabeth Stoner | M | 73 |
Metabasis Therapeutics, Inc.
Metabasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Metabasis Therapeutics, Inc. engages in discovery, development and commercialization of novel drugs for metabolic diseases using the proprietary technology and the knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases. Metabasis was incorporated in April 1997 and is headquartered in La Jolla, CA. | 1 ans |
| Scott J. Hecker | M | - |
Metabasis Therapeutics, Inc.
Metabasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Metabasis Therapeutics, Inc. engages in discovery, development and commercialization of novel drugs for metabolic diseases using the proprietary technology and the knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases. Metabasis was incorporated in April 1997 and is headquartered in La Jolla, CA. | 6 ans |
| Glenn Dourado | M | - |
Metabasis Therapeutics, Inc.
Metabasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Metabasis Therapeutics, Inc. engages in discovery, development and commercialization of novel drugs for metabolic diseases using the proprietary technology and the knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases. Metabasis was incorporated in April 1997 and is headquartered in La Jolla, CA. | 5 ans |
| Sandra Gurrola | F | 57 |
Metabasis Therapeutics, Inc.
Metabasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Metabasis Therapeutics, Inc. engages in discovery, development and commercialization of novel drugs for metabolic diseases using the proprietary technology and the knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases. Metabasis was incorporated in April 1997 and is headquartered in La Jolla, CA. | 2 ans |
Statistiques
| Pays | Relations | % du total |
|---|---|---|
| Etats-Unis | 32 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- David A. Bullough
- Réseau Personnel
